HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The exochelins of pathogenic mycobacteria: unique, highly potent, lipid- and water-soluble hexadentate iron chelators with multiple potential therapeutic uses.

AbstractSIGNIFICANCE:
Exochelins are lipid- and water-soluble siderophores of Mycobacterium tuberculosis with unique properties that endow them with exceptional pharmacologic utility. Exochelins can be utilized as probes to decipher the role of iron in normal and pathological states, and, since they rapidly cross cell membranes and chelate intracellular iron with little or no toxicity, exochelins are potentially useful for the treatment of a number of iron-dependent pathological phenomena.
RECENT ADVANCES:
In animal models, exochelins have been demonstrated to have promise for the treatment of transfusion-related iron overload, restenosis after coronary artery angioplasty, cancer, and oxidative injury associated with acute myocardial infarction and transplantation.
CRITICAL ISSUES:
To be clinically effective, iron chelators should be able to rapidly enter cells and chelate iron at key intracellular sites. Desferri-exochelins, and other lipid-soluble chelators, can readily cross cell membranes and remove intracellular free iron; whereas deferoxamine, which is lipid insoluble, cannot do so. Clinical utility also requires that the chelators be nontoxic, which, we hypothesize, includes the capability to prevent iron from catalyzing free radical reactions which produce •OH or other reactive oxygen species. Lipid-soluble iron chelators currently available for clinical application are bidentate (deferiprone) or tridentate (desferasirox) molecules that do not block all six sites on the iron molecule capable of catalyzing free radical reactions. In contrast, desferri-exochelins are hexadentate molecules, and by forming a one-to-one binding relationship with iron, they prevent free radical reactions.
FUTURE DIRECTIONS:
Clinical studies are needed to assess the utility of desferri-exochelins in the treatment of iron-dependent pathological disorders.
AuthorsLawrence D Horwitz, Marcus A Horwitz
JournalAntioxidants & redox signaling (Antioxid Redox Signal) Vol. 21 Issue 16 Pg. 2246-61 (Dec 01 2014) ISSN: 1557-7716 [Electronic] United States
PMID24684595 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Review)
Chemical References
  • Iron Chelating Agents
  • Peptides, Cyclic
  • Siderophores
  • exochelins
Topics
  • Humans
  • Iron Chelating Agents (therapeutic use)
  • Iron Overload (drug therapy)
  • Mycobacterium (metabolism)
  • Mycobacterium tuberculosis (metabolism)
  • Peptides, Cyclic (metabolism, therapeutic use)
  • Siderophores (metabolism, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: